An Izon Science listing has been pushed down the track after the company secured a $10.5 million investment from private equity firm Bolton Equities.
"We had started preparing for a possible listing prior to this investment, and that is still an option, but it would now be a few years down the track," said Hans van der Voorn, chief executive of the nanotech company, noting that he remains "very supportive" of the NZX.
The company had said it planned to list as early as April. The Christchurch-based company, which has offices in the UK, Boston and Lyon, is the world leader in isolating particles in the nano size range, which are then studied for their role in a range of health conditions and major diseases.
Bolton Equities – a New Zealand private equity investor founded by local businessman Murray Bolton – has taken a 30.4 per cent stake in the company, according to Companies Office filings.